[{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ammoxetine","moa":"5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ammoxetine","moa":"5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ansofaxine HCl","moa":"5-HT\/norepinephrine\/dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Leerink Partners"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ALKS 5461","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ALKS5461","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ALKS5461","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ALKS5461","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ALKS5461","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ALKS5461","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ALKS5461","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ALKS5461","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ALKS5461","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole Fumarate","moa":"5-HT1A\/2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole Fumarate","moa":"5-HT1A\/2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole Fumarate","moa":"5-HT1A\/2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Kanghong Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Chengdu Kanghong Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chengdu Kanghong Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu Kanghong Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Whanin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Whanin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Whanin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Whanin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"HUNGARY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gedeon Richter \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gedeon Richter \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Cybin","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Cybin","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs Drug Development | Drug Safety Navigator","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Clinilabs Drug Development | Drug Safety Navigator","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Clinilabs Drug Development | Drug Safety Navigator"},{"orgOrder":0,"company":"Cybin","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Alliance Global Partners"},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Thermo Fisher Scientific \/ Cybin","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Cybin"},{"orgOrder":0,"company":"Cybin","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Deep Track Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Deep Track Capital"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Facet Life Sciences","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Facet Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Facet Life Sciences \/ Cybin","highestDevelopmentStatusID":"10","companyTruncated":"Facet Life Sciences \/ Cybin"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LYN-005","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LYN-005","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TV-46000","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TV-46000","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Alcobra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Metadoxine","moa":"5-HT2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alcobra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alcobra \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcobra \/ Undisclosed"},{"orgOrder":0,"company":"Alcobra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Metadoxine","moa":"5-HT2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alcobra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Bilayer","sponsorNew":"Alcobra \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcobra \/ Undisclosed"},{"orgOrder":0,"company":"Alcobra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Metadoxine","moa":"5-HT2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alcobra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Alcobra \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcobra \/ Undisclosed"},{"orgOrder":0,"company":"Alcobra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Metadoxine","moa":"5-HT2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alcobra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Alcobra \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcobra \/ Undisclosed"},{"orgOrder":0,"company":"Alcobra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Metadoxine","moa":"5-HT2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alcobra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcobra \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcobra \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioXcel Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Guanfacine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"Maastricht University Medical Center \/ SHIRE PLC"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"US WorldMeds \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"US WorldMeds \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"US WorldMeds \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"US WorldMeds \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"US WorldMeds \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"US WorldMeds \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"US Department of Defense | Gabrail Cancer Center Research | University of Southern California | VA Long Beach Healthcare System | National Intrepid Center of Excellence","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Cycloserine","moa":"Alanine racemase | D-alanylalanine synthetase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ US Department of Defense | Gabrail Cancer Center Research | University of Southern California | VA Long Beach Healthcare System | National Intrepid Center of Excellence","highestDevelopmentStatusID":"10","companyTruncated":"Weill Medical College of Cornell University \/ US Department of Defense | Gabrail Cancer Center Research | University of Southern California | VA Long Beach Healthcare System | National Intrepid Center of Excellence"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"BioSante Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioSante Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioSante Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioSante Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LY03005","moa":"antianxiety","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"LY03005","moa":"antianxiety","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"LY03005","moa":"antianxiety","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"LY03005","moa":"antianxiety","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"LY03005","moa":"antianxiety","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"LY03005","moa":"antianxiety","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"LY03005","moa":"antianxiety","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Luye Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Luye Pharma"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LY03005","moa":"antianxiety","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT 2A receptor (HTR2A)||antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Bain Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":3.2999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":3.2999999999999998,"dosageForm":"Tablet, Modified Release","sponsorNew":"Mitsubishi Tanabe Pharma \/ Bain Capital","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Bain Capital"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Ginseng Extract","moa":"Aryl hydrocarbon receptor; Interleukin-6; Prostaglandin G\/H synthase 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Beer Yaakov - Ness Ziona Mental Health Center","sponsor":"Bar-Ilan University, Israel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Beer Yaakov - Ness Ziona Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beer Yaakov - Ness Ziona Mental Health Center \/ Bar-Ilan University, Israel","highestDevelopmentStatusID":"10","companyTruncated":"Beer Yaakov - Ness Ziona Mental Health Center \/ Bar-Ilan University, Israel"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Physician Services Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Physician Services Incorporated","highestDevelopmentStatusID":"10","companyTruncated":"Centre for Addiction and Mental Health \/ Physician Services Incorporated"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Merck & Co"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"RUSSIA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Tenoten","moa":"Brain protein-specific antibody","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Wellcome Trust | GW Pharmaceutical | Myonex | Cambridge Cognition | Premier Research Group | Diagram | Cambridgeshire and Peterborough NHS Foundation Trust | Oxford Health NHS Foundation Trust | West London NHS Trust | University of Augsburg | Charite Uni","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Oxford \/ Wellcome Trust | GW Pharmaceutical | Myonex | Cambridge Cognition | Premier Research Group | Diagram | Cambridgeshire and Peterborough NHS Foundation Trust | Oxford Health NHS Foundation Trust | West London NHS Trust | University of Augsburg | Charite Uni","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Wellcome Trust | GW Pharmaceutical | Myonex | Cambridge Cognition | Premier Research Group | Diagram | Cambridgeshire and Peterborough NHS Foundation Trust | Oxford Health NHS Foundation Trust | West London NHS Trust | University of Augsburg | Charite Uni"},{"orgOrder":0,"company":"McMaster University","sponsor":"Tilray","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"McMaster University \/ Tilray","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ Tilray"},{"orgOrder":0,"company":"McMaster University","sponsor":"MediPharm Labs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"McMaster University \/ MediPharm Labs","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ MediPharm Labs"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"National Institute on Drug Abuse | International Center for Health Outcomes and Innovation Research | Brains Bioceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ National Institute on Drug Abuse | International Center for Health Outcomes and Innovation Research | Brains Bioceutical","highestDevelopmentStatusID":"10","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ National Institute on Drug Abuse | International Center for Health Outcomes and Innovation Research | Brains Bioceutical"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Curemark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Cm-At","moa":"Chymotrypsin (CTR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Curemark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder","sponsorNew":"Curemark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Curemark \/ Undisclosed"},{"orgOrder":0,"company":"Curemark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Cm-At","moa":"Chymotrypsin (CTR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Curemark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder","sponsorNew":"Curemark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Curemark \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aripiprazole Va","moa":"D2\/5-HT1A\/5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ALKS3831","moa":"D2\/5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ALKS3831","moa":"D2\/5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ALKS3831","moa":"D2\/5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Bilayer","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ALKS3831","moa":"D2\/5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Bilayer","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ALKS3831","moa":"D2\/5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ALKS3831","moa":"D2\/5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Royalty Pharma"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":1.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":1.5,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Merger","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Streeterville Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Streeterville Capital","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Streeterville Capital"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Alvogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Alvogen","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Alvogen"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Private Placement","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-alanylalanine synthetase | Alanine racemase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Meiji Seika Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Bukwang Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bukwang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bukwang Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bukwang Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Sumitomo Pharma America","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Sumitomo Pharma America"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Dainippon Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ Dainippon Sumitomo Pharma America","highestDevelopmentStatusID":"10","companyTruncated":"University of California, Irvine \/ Dainippon Sumitomo Pharma America"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Molindone","moa":"Dopamine D2 receptor||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Molindone","moa":"Dopamine D2 receptor||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Molindone","moa":"Dopamine D2 receptor||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Molindone","moa":"Dopamine D2 receptor||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Molindone","moa":"Dopamine D2 receptor||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Molindone","moa":"Dopamine D2 receptor||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Molindone","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tri-Service General Hospital","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tri-Service General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tri-Service General Hospital \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Tri-Service General Hospital \/ AstraZeneca"},{"orgOrder":0,"company":"Hannover Medical School","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Hannover Medical School","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hannover Medical School \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Hannover Medical School \/ AstraZeneca"},{"orgOrder":0,"company":"Corporation de Recherche en Neuropsycho Pharmacologie de Quebec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Corporation de Recherche en Neuropsycho Pharmacologie de Quebec","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corporation de Recherche en Neuropsycho Pharmacologie de Quebec \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corporation de Recherche en Neuropsycho Pharmacologie de Quebec \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ziprasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ziprasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ziprasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ziprasidone Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"RBP-7000","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"RBP-7000","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"RBP-7000","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"RBP-7000","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"RBP-7000","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Otsuka America Pharmaceutical, Inc.","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka America Pharmaceutical, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka America Pharmaceutical, Inc. \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka America Pharmaceutical, Inc. \/ H. Lundbeck AS"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Iloperidone","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iloperidone","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Iloperidone","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iloperidone","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Korea Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Korea Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Korea Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Korea Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Serge Beaulieu","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Serge Beaulieu","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serge Beaulieu \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Serge Beaulieu \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"ITI-007","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"ITI-007","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ITI-007","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"ITI-007","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Ontario Ministry of Health and Long Term Care | The Canadian Biomarker Integration Network in Depression","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Unity Health Toronto \/ Ontario Ministry of Health and Long Term Care | The Canadian Biomarker Integration Network in Depression","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ Ontario Ministry of Health and Long Term Care | The Canadian Biomarker Integration Network in Depression"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"RevolKa","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RevolKa \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"RevolKa \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Citizens JMP","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Citizens JMP"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Citizens JMP","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Citizens JMP"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Titan Partners Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Tenzing Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.12,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Tenzing Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Tenzing Acquisition"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Tenzing Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.12,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Tenzing Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Tenzing Acquisition"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Milsaperidone","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Milsaperidone","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Tangent Data Services","sponsor":"Stanley Medical Research Institute | MediStat | PCI Pharma Services | S.C. IMUNOTEHNOMED S.R.L. | Tangent Data Srl","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tangent Data Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Tangent Data Services \/ Stanley Medical Research Institute | MediStat | PCI Pharma Services | S.C. IMUNOTEHNOMED S.R.L. | Tangent Data Srl","highestDevelopmentStatusID":"10","companyTruncated":"Tangent Data Services \/ Stanley Medical Research Institute | MediStat | PCI Pharma Services | S.C. IMUNOTEHNOMED S.R.L. | Tangent Data Srl"},{"orgOrder":0,"company":"Iris Sommer","sponsor":"Julius Center | Rudolf Magnus Institute - University of Utrecht | GGZ Eindhoven | Academisch Medisch Centrum - Universiteit van Amsterdam | GGZ Centraal | Altrecht GGZ | Reinier van Arkel Group | Ziekenhuis Netwerk Antwerpen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen receptor beta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Iris Sommer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iris Sommer \/ Julius Center | Rudolf Magnus Institute - University of Utrecht | GGZ Eindhoven | Academisch Medisch Centrum - Universiteit van Amsterdam | GGZ Centraal | Altrecht GGZ | Reinier van Arkel Group | Ziekenhuis Netwerk Antwerpen","highestDevelopmentStatusID":"10","companyTruncated":"Iris Sommer \/ Julius Center | Rudolf Magnus Institute - University of Utrecht | GGZ Eindhoven | Academisch Medisch Centrum - Universiteit van Amsterdam | GGZ Centraal | Altrecht GGZ | Reinier van Arkel Group | Ziekenhuis Netwerk Antwerpen"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NWP09","moa":"Factor VIII","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Union Pharmaceutical Factory","sponsor":"R&G PharmaStudies Co","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buagafuran","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Beijing Union Pharmaceutical Factory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Union Pharmaceutical Factory \/ R&G PharmaStudies Co","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Union Pharmaceutical Factory \/ R&G PharmaStudies Co"},{"orgOrder":0,"company":"Beijing Union Pharmaceutical Factory","sponsor":"R&G PharmaStudies Co","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buagafuran","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Beijing Union Pharmaceutical Factory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Union Pharmaceutical Factory \/ R&G PharmaStudies Co","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Union Pharmaceutical Factory \/ R&G PharmaStudies Co"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"EDGEMONT PHARMS LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Lorazepam","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"EDGEMONT PHARMS LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EDGEMONT PHARMS LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EDGEMONT PHARMS LLC \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Feinstein Institutes \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein Institutes \/ Undisclosed"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"||GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":3.1299999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":3.1299999999999999,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ethypharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Ethypharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ethypharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ethypharm \/ Undisclosed"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA(A) receptor alpha-1 (GABRA1)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kelly Allison","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Kelly Allison","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kelly Allison \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Kelly Allison \/ Novo Nordisk"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"University of Ottawa","sponsor":"McGill University | Queen's University | University Health Network, Toronto | Ontario Shores Centre for Mental Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Ottawa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Ottawa \/ McGill University | Queen's University | University Health Network, Toronto | Ontario Shores Centre for Mental Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"University of Ottawa \/ McGill University | Queen's University | University Health Network, Toronto | Ontario Shores Centre for Mental Health Sciences"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"VA Ann Arbor Healthcare System","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VA Ann Arbor Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Ann Arbor Healthcare System \/ University of Michigan","highestDevelopmentStatusID":"10","companyTruncated":"VA Ann Arbor Healthcare System \/ University of Michigan"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"Abraham Nunes","sponsor":"Nova Scotia Health Authority","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Abraham Nunes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abraham Nunes \/ Nova Scotia Health Authority","highestDevelopmentStatusID":"10","companyTruncated":"Abraham Nunes \/ Nova Scotia Health Authority"},{"orgOrder":0,"company":"HOPE Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Merger","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"HOPE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HOPE Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"HOPE Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Nephron Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Nephron Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Nephron Pharmaceuticals Corporation"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Anson Funds","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Anson Funds","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Anson Funds"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Smith & Sauer","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Smith & Sauer","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Smith & Sauer"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Target Health Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRx Pharmaceuticals \/ Target Health Inc.","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Target Health Inc."},{"orgOrder":0,"company":"Awakn Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Awakn Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Awakn Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Awakn Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Undisclosed","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Undisclosed \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Undisclosed \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Rapastinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Osavampator","moa":"Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"MGGM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MGGM","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MGGM \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MGGM \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Relmada Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Esmethadone Hydrochloride","moa":"GRIN","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Arbormentis","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Arbormentis"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pomaglumetad Methionil","moa":"GRM2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital","sponsor":"t-biyoteknoloji labaratuvar estetik medikal kozmetik san. ve tic. ltd. ?ti.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TURKEY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital \/ t-biyoteknoloji labaratuvar estetik medikal kozmetik san. ve tic. ltd. ?ti.","highestDevelopmentStatusID":"10","companyTruncated":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital \/ t-biyoteknoloji labaratuvar estetik medikal kozmetik san. ve tic. ltd. ?ti."},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"HTR2A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"HTR2A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"HTR2A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"HTR2A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"HTR2A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Millet Roux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Passiflora","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Millet Roux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Millet Roux \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Millet Roux \/ Undisclosed"},{"orgOrder":0,"company":"Pascoe Natural Healthcare","sponsor":"Daacro","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Passiflora Incarnata","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pascoe Natural Healthcare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pascoe Natural Healthcare \/ Daacro","highestDevelopmentStatusID":"10","companyTruncated":"Pascoe Natural Healthcare \/ Daacro"},{"orgOrder":0,"company":"Sichuan Jishengtang Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Shugan Jieyu","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sichuan Jishengtang Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sichuan Jishengtang Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sichuan Jishengtang Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Jiaotong University School of Medicine","sponsor":"Shanghai Xuhui District Mental Health Center | Shanghai Pudong Nanhui Mental Health Center | Suzhou Psychiatric Hospital | Second Xiangya Hospital, Central South University | Guangzhou Psychiatric Hospital | Shenzhen Fushan Biotech Co., Ltd. | Tianjin And","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Jiaotong University School of Medicine \/ Shanghai Xuhui District Mental Health Center | Shanghai Pudong Nanhui Mental Health Center | Suzhou Psychiatric Hospital | Second Xiangya Hospital, Central South University | Guangzhou Psychiatric Hospital | Shenzhen Fushan Biotech Co., Ltd. | Tianjin And","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Jiaotong University School of Medicine \/ Shanghai Xuhui District Mental Health Center | Shanghai Pudong Nanhui Mental Health Center | Suzhou Psychiatric Hospital | Second Xiangya Hospital, Central South University | Guangzhou Psychiatric Hospital | Shenzhen Fushan Biotech Co., Ltd. | Tianjin And"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CERC-501","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CERC-501","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CERC-501","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CERC-501","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CERC-501","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Abu Dhabi Growth Fund","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Abu Dhabi Growth Fund","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ Abu Dhabi Growth Fund"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"BlackThorn Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ BlackThorn Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ BlackThorn Therapeutics"},{"orgOrder":0,"company":"Orexo","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orexo \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Orexo","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orexo \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ Indivior","highestDevelopmentStatusID":"10","companyTruncated":"New York State Psychiatric Institute \/ Indivior"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"Alkermes Plc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ Alkermes Plc","highestDevelopmentStatusID":"10","companyTruncated":"New York State Psychiatric Institute \/ Alkermes Plc"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Titan Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"T. John Winhusen, PhD","sponsor":"National Institute on Drug Abuse | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"T. John Winhusen, PhD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"T. John Winhusen, PhD \/ National Institute on Drug Abuse | The Emmes Company, LLC","highestDevelopmentStatusID":"10","companyTruncated":"T. John Winhusen, PhD \/ National Institute on Drug Abuse | The Emmes Company, LLC"},{"orgOrder":0,"company":"T. John Winhusen, PhD","sponsor":"National Institute on Drug Abuse | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"T. John Winhusen, PhD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"T. John Winhusen, PhD \/ National Institute on Drug Abuse | The Emmes Company, LLC","highestDevelopmentStatusID":"10","companyTruncated":"T. John Winhusen, PhD \/ National Institute on Drug Abuse | The Emmes Company, LLC"},{"orgOrder":0,"company":"T. John Winhusen, PhD","sponsor":"National Institute on Drug Abuse | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"T. John Winhusen, PhD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"T. John Winhusen, PhD \/ National Institute on Drug Abuse | The Emmes Company, LLC","highestDevelopmentStatusID":"10","companyTruncated":"T. John Winhusen, PhD \/ National Institute on Drug Abuse | The Emmes Company, LLC"},{"orgOrder":0,"company":"Yih-Ing Hser","sponsor":"National Institute on Drug Abuse | National Institutes of Health | The Emmes Company, LLC | University of California, Los Angeles | RAND Corporation | Cornell University | Oregon Health and Science University | University of Illinois, Chicago | University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Yih-Ing Hser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yih-Ing Hser \/ National Institute on Drug Abuse | National Institutes of Health | The Emmes Company, LLC | University of California, Los Angeles | RAND Corporation | Cornell University | Oregon Health and Science University | University of Illinois, Chicago | University","highestDevelopmentStatusID":"10","companyTruncated":"Yih-Ing Hser \/ National Institute on Drug Abuse | National Institutes of Health | The Emmes Company, LLC | University of California, Los Angeles | RAND Corporation | Cornell University | Oregon Health and Science University | University of Illinois, Chicago | University"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Azetukalner","moa":"KCNQ2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenon Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Azetukalner","moa":"KCNQ2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenon Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Azetukalner","moa":"KCNQ2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenon Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"Lead; Iron; Manganese cation","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":2.7000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":2.7000000000000002,"dosageForm":"Capsule","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":2.7000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":2.7000000000000002,"dosageForm":"Capsule","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":2.7000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":2.7000000000000002,"dosageForm":"Capsule","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Sosei Heptares","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Sosei Heptares","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Sosei Heptares"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Artemis Biotech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Partnership","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Artemis Biotech","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Artemis Biotech"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"French Government","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Funding","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ French Government","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ French Government"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Funding","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Bpifrance"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"CEA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Collaboration","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ CEA","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ CEA"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Financing","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Kwang Dong Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Kwang Dong Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2140023","moa":"Metabotropic glutamate receptor 3 | Metabotropic glutamate receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denovo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2140023","moa":"Metabotropic glutamate receptor 3 | Metabotropic glutamate receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denovo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2140023","moa":"Metabotropic glutamate receptor 3 | Metabotropic glutamate receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denovo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2140023","moa":"Metabotropic glutamate receptor 3 | Metabotropic glutamate receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denovo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2140023","moa":"Metabotropic glutamate receptor 3 | Metabotropic glutamate receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denovo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2140023","moa":"Metabotropic glutamate receptor 3 | Metabotropic glutamate receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denovo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"LY2140023","moa":"Metabotropic glutamate receptor 3 | Metabotropic glutamate receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denovo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Mood and Anxiety Research, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Selegiline Hydrochloride","moa":"Monoamine oxidase B","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mood and Anxiety Research, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Mood and Anxiety Research, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mood and Anxiety Research, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Canadian Institutes of Health Research | Providence Healthcare | Innerchange Charitable Society","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydromorphone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Canadian Institutes of Health Research | Providence Healthcare | Innerchange Charitable Society","highestDevelopmentStatusID":"10","companyTruncated":"University of British Columbia \/ Canadian Institutes of Health Research | Providence Healthcare | Innerchange Charitable Society"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Relmada Therapeutics \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Syneos Health"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Sponsor-Investigator","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Sponsor-Investigator","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Sponsor-Investigator"},{"orgOrder":0,"company":"M. Eugenia Socias","sponsor":"Canadian Institutes of Health Research | Vancouver Foundation | Mayne Pharma Do Brasil Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Morphine Sulfate","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"M. Eugenia Socias","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M. Eugenia Socias \/ Canadian Institutes of Health Research | Vancouver Foundation | Mayne Pharma Do Brasil Ltda","highestDevelopmentStatusID":"10","companyTruncated":"M. Eugenia Socias \/ Canadian Institutes of Health Research | Vancouver Foundation | Mayne Pharma Do Brasil Ltda"},{"orgOrder":0,"company":"Elite Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Elite Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Elite Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elite Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Samidorphan","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Samidorphan","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Samidorphan","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor||Mu opioid receptor | Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virginia Commonwealth University \/ Indivior","highestDevelopmentStatusID":"10","companyTruncated":"Virginia Commonwealth University \/ Indivior"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor||Mu opioid receptor | Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virginia Commonwealth University \/ Indivior","highestDevelopmentStatusID":"10","companyTruncated":"Virginia Commonwealth University \/ Indivior"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Hypericum Perforatum Dry Extract","moa":"Multiple (neurotransmitter systems)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Bayer AG"},{"orgOrder":0,"company":"Braeburn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CAS 52485-79-7","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Braeburn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Braeburn \/ Undisclosed"},{"orgOrder":0,"company":"Braeburn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CAS 52485-79-7","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Braeburn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Braeburn \/ Undisclosed"},{"orgOrder":0,"company":"Braeburn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CAS 52485-79-7","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Braeburn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Braeburn \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.19,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":14,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":14,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":14,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":14,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.46000000000000002,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.46000000000000002,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.5,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Royalty Pharma"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Segal Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Segal Trials","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Segal Trials"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Karuna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PureTech Health \/ Karuna Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"European Group for Research In Schizophrenia","sponsor":"Bristol Myers Squibb | University Medical Center Groningen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"European Group for Research In Schizophrenia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"European Group for Research In Schizophrenia \/ Bristol Myers Squibb | University Medical Center Groningen","highestDevelopmentStatusID":"10","companyTruncated":"European Group for Research In Schizophrenia \/ Bristol Myers Squibb | University Medical Center Groningen"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Target Health Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"N-Desethyloxybutynin","moa":"D-Ala-D-Ala ligase A||Muscarinic receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRx Pharmaceuticals \/ Target Health Inc.","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Target Health Inc."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Prevail Infoworks","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"N-Desethyloxybutynin","moa":"D-Ala-D-Ala ligase A||Muscarinic receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRx Pharmaceuticals \/ Prevail Infoworks","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Prevail Infoworks"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Target Health Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"N-Desethyloxybutynin","moa":"D-Ala-D-Ala ligase A||Muscarinic receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRx Pharmaceuticals \/ Target Health Inc.","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Target Health Inc."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Prevail Infoworks","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"N-Desethyloxybutynin","moa":"D-Ala-D-Ala ligase A||Muscarinic receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRx Pharmaceuticals \/ Prevail Infoworks","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Prevail Infoworks"},{"orgOrder":0,"company":"University of Auckland, New Zealand","sponsor":"Lakes District Health Board | Brunel University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Auckland, New Zealand","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Auckland, New Zealand \/ Lakes District Health Board | Brunel University","highestDevelopmentStatusID":"10","companyTruncated":"University of Auckland, New Zealand \/ Lakes District Health Board | Brunel University"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"FORUM Pharmaceuticals","sponsor":"Syneos Health | NeuroCog Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"EVP-6124","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"FORUM Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FORUM Pharmaceuticals \/ Syneos Health | NeuroCog Trials","highestDevelopmentStatusID":"10","companyTruncated":"FORUM Pharmaceuticals \/ Syneos Health | NeuroCog Trials"},{"orgOrder":0,"company":"FORUM Pharmaceuticals","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"EVP-6124","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"FORUM Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FORUM Pharmaceuticals \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"FORUM Pharmaceuticals \/ Syneos Health"},{"orgOrder":0,"company":"FORUM Pharmaceuticals","sponsor":"Syneos Health | NeuroCog Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"EVP-6124","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"FORUM Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FORUM Pharmaceuticals \/ Syneos Health | NeuroCog Trials","highestDevelopmentStatusID":"10","companyTruncated":"FORUM Pharmaceuticals \/ Syneos Health | NeuroCog Trials"},{"orgOrder":0,"company":"FORUM Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"EVP-6124","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"FORUM Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FORUM Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FORUM Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Propel Bio Partners LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.12,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Propel Bio Partners LLC","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Propel Bio Partners LLC"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Silicon Valley Bank","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Citizens Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.050000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Citizens Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Citizens Capital Markets"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Citizens Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.050000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Citizens Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Citizens Capital Markets"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Omnicom","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Omnicom","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Omnicom"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"GSK | McNeil AB","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"McNeil Consumer Health \/ GSK | McNeil AB","highestDevelopmentStatusID":"10","companyTruncated":"McNeil Consumer Health \/ GSK | McNeil AB"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"McNeil AB | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McNeil Consumer Health \/ McNeil AB | GSK","highestDevelopmentStatusID":"10","companyTruncated":"McNeil Consumer Health \/ McNeil AB | GSK"},{"orgOrder":0,"company":"Rose Research Center","sponsor":"Foundation for a Smoke Free World","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Rose Research Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Rose Research Center \/ Foundation for a Smoke Free World","highestDevelopmentStatusID":"10","companyTruncated":"Rose Research Center \/ Foundation for a Smoke Free World"},{"orgOrder":0,"company":"Rose Research Center","sponsor":"Global Action to End Smoking","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Rose Research Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Rose Research Center \/ Global Action to End Smoking","highestDevelopmentStatusID":"10","companyTruncated":"Rose Research Center \/ Global Action to End Smoking"},{"orgOrder":0,"company":"University of Auckland, New Zealand","sponsor":"Health New Zealand Ltd, Christchurch, New Zealand | Auckland District Health Board","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Auckland, New Zealand","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Liquid","sponsorNew":"University of Auckland, New Zealand \/ Health New Zealand Ltd, Christchurch, New Zealand | Auckland District Health Board","highestDevelopmentStatusID":"10","companyTruncated":"University of Auckland, New Zealand \/ Health New Zealand Ltd, Christchurch, New Zealand | Auckland District Health Board"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TC-5214","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Catalyst Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Catalyst Biosciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TC-5214","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Catalyst Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Catalyst Biosciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TC-5214","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Catalyst Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Catalyst Biosciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TC-5214","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Catalyst Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Catalyst Biosciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TC-5214","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Catalyst Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Catalyst Biosciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TC-5214","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"National Institute on Drug Abuse | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ National Institute on Drug Abuse | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of California, San Francisco \/ National Institute on Drug Abuse | Pfizer Inc"},{"orgOrder":0,"company":"State University of New York at Buffalo","sponsor":"National Cancer Institute | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"State University of New York at Buffalo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"State University of New York at Buffalo \/ National Cancer Institute | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"State University of New York at Buffalo \/ National Cancer Institute | Pfizer Inc"},{"orgOrder":0,"company":"Duke University","sponsor":"National Institute on Drug Abuse | Philip Morris USA, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Duke University \/ National Institute on Drug Abuse | Philip Morris USA, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Duke University \/ National Institute on Drug Abuse | Philip Morris USA, Inc"},{"orgOrder":0,"company":"Duke University","sponsor":"National Institute on Drug Abuse | Philip Morris USA, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Duke University \/ National Institute on Drug Abuse | Philip Morris USA, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Duke University \/ National Institute on Drug Abuse | Philip Morris USA, Inc"},{"orgOrder":0,"company":"Duke University","sponsor":"National Institute on Drug Abuse | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Duke University \/ National Institute on Drug Abuse | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Duke University \/ National Institute on Drug Abuse | Pfizer Inc"},{"orgOrder":0,"company":"Duke University","sponsor":"Intelligent Automation | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Duke University \/ Intelligent Automation | National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"Duke University \/ Intelligent Automation | National Institute on Drug Abuse"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MED2005","moa":"Nitric oxide pathway","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Futura Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Futura Medical \/ Undisclosed"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MED2005","moa":"Nitric oxide pathway","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Futura Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Futura Medical \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Rose Research Center","sponsor":"Foundation for a Smoke Free World","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Rose Research Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rose Research Center \/ Foundation for a Smoke Free World","highestDevelopmentStatusID":"10","companyTruncated":"Rose Research Center \/ Foundation for a Smoke Free World"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Dr. Vince Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Dr. Vince Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Dr. Vince Clinical Research"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Cingulate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Societal CDMO \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Societal CDMO \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indegene","sponsor":"Cingulate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indegene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Indegene \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Indegene \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Rho Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics \/ Rho Inc","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Rho Inc"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cingulate Therapeutics \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Premier Research Group"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Edivoxetine","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Duke University","sponsor":"Forest Laboratories | Institute for Advanced Medical Research, Alpharetta, GA","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Levomilnacipran","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Forest Laboratories | Institute for Advanced Medical Research, Alpharetta, GA","highestDevelopmentStatusID":"10","companyTruncated":"Duke University \/ Forest Laboratories | Institute for Advanced Medical Research, Alpharetta, GA"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Levomilnacipran","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Levomilnacipran","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2216684","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pseudoephedrine Sulfate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Venlafaxine","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Venlafaxine","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RHODES PHARMACEUTICALS LP","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RHODES PHARMACEUTICALS LP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"10","companyTruncated":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"RHODES PHARMACEUTICALS LP","sponsor":"Purdue Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RHODES PHARMACEUTICALS LP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RHODES PHARMACEUTICALS LP \/ Purdue Pharma","highestDevelopmentStatusID":"10","companyTruncated":"RHODES PHARMACEUTICALS LP \/ Purdue Pharma"},{"orgOrder":0,"company":"RHODES PHARMACEUTICALS LP","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RHODES PHARMACEUTICALS LP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"10","companyTruncated":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"RHODES PHARMACEUTICALS LP","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RHODES PHARMACEUTICALS LP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"10","companyTruncated":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"RHODES PHARMACEUTICALS LP","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RHODES PHARMACEUTICALS LP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"10","companyTruncated":"RHODES PHARMACEUTICALS LP \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Purdue Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Purdue Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Orient Pharma","sponsor":"Durect","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orient Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orient Pharma \/ Durect","highestDevelopmentStatusID":"10","companyTruncated":"Orient Pharma \/ Durect"},{"orgOrder":0,"company":"Orient Pharma","sponsor":"Durect","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orient Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orient Pharma \/ Durect","highestDevelopmentStatusID":"10","companyTruncated":"Orient Pharma \/ Durect"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Desvenlafaxine Succinate","moa":"Norepinephrine transporter | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Pfizer Inc"},{"orgOrder":0,"company":"Shionogi","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Eli Lilly"},{"orgOrder":0,"company":"Shionogi","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Eli Lilly"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"SHP465","moa":"Norepinephrine\/dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"SHP465","moa":"Norepinephrine\/dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SHP465","moa":"Norepinephrine\/dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SHP465","moa":"Norepinephrine\/dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"SHP465","moa":"Norepinephrine\/dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SHP465","moa":"Norepinephrine\/dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"KP415","moa":"Norepinephrine\/dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zevra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"KP415","moa":"Norepinephrine\/dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zevra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ALKS9072","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ALKS9072","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ALKS9072","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Harm Reduction Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Alkermes Plc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of California, Los Angeles \/ Alkermes Plc","highestDevelopmentStatusID":"10","companyTruncated":"University of California, Los Angeles \/ Alkermes Plc"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"National Institute on Drug Abuse | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ National Institute on Drug Abuse | The Emmes Company, LLC","highestDevelopmentStatusID":"10","companyTruncated":"UT Southwestern Medical Center \/ National Institute on Drug Abuse | The Emmes Company, LLC"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"OPRM1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"OPRM1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"OPRM1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Royalty Pharma"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"IRCCS Eugenio Medea","sponsor":"DMF srl (Dietetic Metabolic Food)","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IRCCS Eugenio Medea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRCCS Eugenio Medea \/ DMF srl (Dietetic Metabolic Food)","highestDevelopmentStatusID":"10","companyTruncated":"IRCCS Eugenio Medea \/ DMF srl (Dietetic Metabolic Food)"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oil","sponsorNew":"University of Cincinnati \/ Royal DSM","highestDevelopmentStatusID":"10","companyTruncated":"University of Cincinnati \/ Royal DSM"},{"orgOrder":0,"company":"G\u00f6teborg University","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"G\u00f6teborg University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G\u00f6teborg University \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"G\u00f6teborg University \/ CSL Vifor"},{"orgOrder":0,"company":"Johannes Gutenberg University Mainz","sponsor":"Engelhard Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johannes Gutenberg University Mainz","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johannes Gutenberg University Mainz \/ Engelhard Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Johannes Gutenberg University Mainz \/ Engelhard Arzneimittel"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Avanafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Avanafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"iX Biopharma","sponsor":"Linear","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"iX Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Wafer","sponsorNew":"iX Biopharma \/ Linear","highestDevelopmentStatusID":"10","companyTruncated":"iX Biopharma \/ Linear"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"Laborat\u00f3rio Teuto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Laborat\u00f3rio Teuto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laborat\u00f3rio Teuto \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laborat\u00f3rio Teuto \/ Undisclosed"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"||Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Emotional Brain BV","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"||Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Emotional Brain BV","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Emotional Brain BV"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Futura Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Futura Medical \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Digital Offering, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Digital Offering, LLC","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Digital Offering, LLC"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"IntelGenx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ IntelGenx"},{"orgOrder":0,"company":"Lidia Larra\u00f1aga","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lidia Larra\u00f1aga","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lidia Larra\u00f1aga \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lidia Larra\u00f1aga \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Udenafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Dong-A Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Udenafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Dong-A Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Abdi Ibrahim","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TURKEY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Udenafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Abdi Ibrahim","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdi Ibrahim \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abdi Ibrahim \/ Undisclosed"},{"orgOrder":0,"company":"Warner Chilcott Company, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Udenafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Warner Chilcott Company, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Warner Chilcott Company, LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Warner Chilcott Company, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Warner Chilcott Company, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Udenafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Warner Chilcott Company, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Warner Chilcott Company, LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Warner Chilcott Company, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vigonvita Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vigonvita Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vigonvita Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vigonvita Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vigonvita Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vigonvita Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigonvita Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vigonvita Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigonvita Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vigonvita Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigonvita Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vigonvita Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigonvita Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vigonvita Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Sharmin Ghaznavi","sponsor":"Compass Pathways","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sharmin Ghaznavi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sharmin Ghaznavi \/ Compass Pathways","highestDevelopmentStatusID":"10","companyTruncated":"Sharmin Ghaznavi \/ Compass Pathways"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Greenbrook TMS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Greenbrook TMS","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Greenbrook TMS"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Hercules Capital"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Mindful Health Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Mindful Health Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Mindful Health Solutions"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Hackensack Meridian Health","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Hackensack Meridian Health"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Journey Clinical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Journey Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Journey Clinical"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.28999999999999998,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ TCGX"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"The Centre for Mental Health Research and Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ The Centre for Mental Health Research and Innovation","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ The Centre for Mental Health Research and Innovation"},{"orgOrder":0,"company":"Usona Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Usona Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Usona Institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Usona Institute \/ Undisclosed"},{"orgOrder":0,"company":"Usona Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Usona Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Usona Institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Usona Institute \/ Undisclosed"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trazodone Hydrochloride","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angelini Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Angelini Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Braeburn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Braeburn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Braeburn \/ Undisclosed"},{"orgOrder":0,"company":"Braeburn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Braeburn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Braeburn \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Lyndra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Thermo Fisher Scientific \/ Lyndra Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Lyndra Therapeutics"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Aig Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Aig Investments","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Aig Investments"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sarissa Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series E Financing","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Sarissa Capital","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Sarissa Capital"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of North Carolina \/ US Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"University of North Carolina \/ US Department of Defense"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Premier Research Group"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Premier Research Group"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ziprasidone Hydrochloride","moa":"Serotonin 2c (5-HT2c) receptor | Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Agomelatine","moa":"Serotonin 2c (5-HT2c) receptor | Melatonin receptor||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Agomelatine","moa":"Serotonin 2c (5-HT2c) receptor | Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Agomelatine","moa":"Serotonin 2c (5-HT2c) receptor | Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Adenomed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Divestment","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Adenomed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Adenomed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Boudicca Dx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Boudicca Dx","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Boudicca Dx"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Maxim Group LLC"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Adial Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Thermo Fisher Scientific \/ Adial Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Adial Pharmaceuticals"},{"orgOrder":0,"company":"Bayside Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bayside Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayside Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayside Health \/ Undisclosed"},{"orgOrder":0,"company":"Scotmann Pharmaceuticals","sponsor":"Rawalpindi Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"PAKISTAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Scotmann Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College","highestDevelopmentStatusID":"10","companyTruncated":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Johns Hopkins University \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masupirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Clomipramine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SYMYOO Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SYMYOO Inc \/ Undisclosed"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Clomipramine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SYMYOO Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SYMYOO Inc \/ Undisclosed"},{"orgOrder":0,"company":"Boston Medical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dapoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boston Medical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Medical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boston Medical Group \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"University of Toronto | University of Calgary | University of British Columbia | McGill University | Queen's University | Centre for Addiction and Mental Health | McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ University of Toronto | University of Calgary | University of British Columbia | McGill University | Queen's University | Centre for Addiction and Mental Health | McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"University Health Network, Toronto \/ University of Toronto | University of Calgary | University of British Columbia | McGill University | Queen's University | Centre for Addiction and Mental Health | McMaster University"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan | Simon Fraser University | Unity Health Toronto | Baycrest | Centre for Addiction and M","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan | Simon Fraser University | Unity Health Toronto | Baycrest | Centre for Addiction and M","highestDevelopmentStatusID":"10","companyTruncated":"University Health Network, Toronto \/ Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan | Simon Fraser University | Unity Health Toronto | Baycrest | Centre for Addiction and M"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"University of Pennsylvania \/ Forest Laboratories"},{"orgOrder":0,"company":"Laborat\u00f3rio Catarinense","sponsor":"Universidade Federal do Ceara | Financiadora de Estudos e Projetos","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Laborat\u00f3rio Catarinense","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Laborat\u00f3rio Catarinense \/ Universidade Federal do Ceara | Financiadora de Estudos e Projetos","highestDevelopmentStatusID":"10","companyTruncated":"Laborat\u00f3rio Catarinense \/ Universidade Federal do Ceara | Financiadora de Estudos e Projetos"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Harvard Medical School (HMS and HSDM)","sponsor":"Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harvard Medical School (HMS and HSDM)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Medical School (HMS and HSDM) \/ Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men","highestDevelopmentStatusID":"10","companyTruncated":"Harvard Medical School (HMS and HSDM) \/ Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men"},{"orgOrder":0,"company":"Harvard Medical School (HMS and HSDM)","sponsor":"National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harvard Medical School (HMS and HSDM)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Medical School (HMS and HSDM) \/ National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal","highestDevelopmentStatusID":"10","companyTruncated":"Harvard Medical School (HMS and HSDM) \/ National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fluvoxamine","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AbbVie Inc \/ Meiji Seika Pharma","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of Melbourne \/ Pfizer Inc"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Desvenlafaxine Succinate","moa":"Serotonin transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venlafaxine Hydrochloride","moa":"Serotonin transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Sustained Release","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Toludesvenlafaxine HCl","moa":"Serotonin\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Healing Breakthrough","sponsor":"San Diego Veterans Healthcare System | National Center for PTSD | White River Junction VA Medical Center | Lykos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2||Synaptic vesicular amine transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; Sodium-dependent dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Healing Breakthrough","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healing Breakthrough \/ San Diego Veterans Healthcare System | National Center for PTSD | White River Junction VA Medical Center | Lykos Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Healing Breakthrough \/ San Diego Veterans Healthcare System | National Center for PTSD | White River Junction VA Medical Center | Lykos Therapeutics"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2||Synaptic vesicular amine transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; Sodium-dependent dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2||Synaptic vesicular amine transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; Sodium-dependent dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2||Synaptic vesicular amine transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; Sodium-dependent dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Leslie Morland","sponsor":"Healing Breakthrough | Lykos Therapeutics | San Diego Veterans Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2||Synaptic vesicular amine transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; Sodium-dependent dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Leslie Morland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leslie Morland \/ Healing Breakthrough | Lykos Therapeutics | San Diego Veterans Healthcare System","highestDevelopmentStatusID":"10","companyTruncated":"Leslie Morland \/ Healing Breakthrough | Lykos Therapeutics | San Diego Veterans Healthcare System"},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Maps Laboratories Private Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maps Laboratories Private Limited \/ Undisclosed"},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Steven & Alexandra Cohen Foundation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Funding","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Maps Laboratories Private Limited \/ Steven & Alexandra Cohen Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Maps Laboratories Private Limited \/ Steven & Alexandra Cohen Foundation"},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"||SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Maps Laboratories Private Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maps Laboratories Private Limited \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Helena","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Series A Financing","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Helena","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Helena"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optimi Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Optimi Health \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Midomafetamine HCl","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine HCl","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Midomafetamine HCl","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Midomafetamine HCl","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Centanafadine hydrochloride","moa":"SLC6A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Centanafadine hydrochloride","moa":"SLC6A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iclepertin","moa":"GlyT1||SLC6A9","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iclepertin","moa":"GlyT1||SLC6A9","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Iclepertin","moa":"GlyT1||SLC6A9","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Iclepertin","moa":"GlyT1||SLC6A9","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iclepertin","moa":"SLC6A9","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iclepertin","moa":"SLC6A9","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Iclepertin","moa":"SLC6A9","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iclepertin","moa":"SLC6A9","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Iclepertin","moa":"SLC6A9","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"EA Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ EA Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ EA Pharma"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"QATAR","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Rose Research Center","sponsor":"Foundation for a Smoke Free World","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Rose Research Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rose Research Center \/ Foundation for a Smoke Free World","highestDevelopmentStatusID":"10","companyTruncated":"Rose Research Center \/ Foundation for a Smoke Free World"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"University of Connecticut | Yale University | National Institute on Alcohol Abuse and Alcoholism | VA Connecticut Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ University of Connecticut | Yale University | National Institute on Alcohol Abuse and Alcoholism | VA Connecticut Healthcare System","highestDevelopmentStatusID":"10","companyTruncated":"Virginia Commonwealth University \/ University of Connecticut | Yale University | National Institute on Alcohol Abuse and Alcoholism | VA Connecticut Healthcare System"},{"orgOrder":0,"company":"South West Sydney Local Health District","sponsor":"National Health and Medical Research Council, Australia | University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"South West Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"South West Sydney Local Health District \/ National Health and Medical Research Council, Australia | University of Sydney","highestDevelopmentStatusID":"10","companyTruncated":"South West Sydney Local Health District \/ National Health and Medical Research Council, Australia | University of Sydney"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Endoceutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Prasterone","moa":"steroids (androgens","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Endoceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Insert","sponsorNew":"Endoceutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Endoceutics \/ Undisclosed"},{"orgOrder":0,"company":"Endoceutics","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Prasterone","moa":"steroids (androgens","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Endoceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Insert","sponsorNew":"Endoceutics \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Endoceutics \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"National Cheng-Kung University Hospital","sponsor":"National Health Research Institutes, Taiwan | TTY BIOPHARM CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Cheng-Kung University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cheng-Kung University Hospital \/ National Health Research Institutes, Taiwan | TTY BIOPHARM CO LTD","highestDevelopmentStatusID":"10","companyTruncated":"National Cheng-Kung University Hospital \/ National Health Research Institutes, Taiwan | TTY BIOPHARM CO LTD"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Canadian Institutes of Health Research | Eli Lilly | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Canadian Institutes of Health Research | Eli Lilly | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"University of British Columbia \/ Canadian Institutes of Health Research | Eli Lilly | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Lindner Center of HOPE","sponsor":"SHIRE PLC | University of Cincinnati","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lindner Center of HOPE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindner Center of HOPE \/ SHIRE PLC | University of Cincinnati","highestDevelopmentStatusID":"10","companyTruncated":"Lindner Center of HOPE \/ SHIRE PLC | University of Cincinnati"},{"orgOrder":0,"company":"Lindner Center of HOPE","sponsor":"SHIRE PLC | University of Cincinnati","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lindner Center of HOPE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindner Center of HOPE \/ SHIRE PLC | University of Cincinnati","highestDevelopmentStatusID":"10","companyTruncated":"Lindner Center of HOPE \/ SHIRE PLC | University of Cincinnati"},{"orgOrder":0,"company":"Lindner Center of HOPE","sponsor":"SHIRE PLC | University of Cincinnati","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lindner Center of HOPE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindner Center of HOPE \/ SHIRE PLC | University of Cincinnati","highestDevelopmentStatusID":"10","companyTruncated":"Lindner Center of HOPE \/ SHIRE PLC | University of Cincinnati"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"University Ghent","sponsor":"Fund for Scientific Research, Flanders, Belgium | SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University Ghent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University Ghent \/ Fund for Scientific Research, Flanders, Belgium | SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"University Ghent \/ Fund for Scientific Research, Flanders, Belgium | SHIRE PLC"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ulotaront","moa":"TAAR1||Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0.89000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.89000000000000001,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Zicronapine","moa":"tricyclic compounds","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Zicronapine","moa":"tricyclic compounds","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Natusgerin","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"323U66","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"36404","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"36404","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Vaxart","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"3\\'-aminomethylnicotine-P. Aeruginosa r-exoprotein A Conjugate Vaccine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxart \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vaxart \/ Undisclosed"},{"orgOrder":0,"company":"Vaxart","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"3\\'-aminomethylnicotine-P. Aeruginosa r-exoprotein A Conjugate Vaccine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxart \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Vaxart \/ GSK"},{"orgOrder":0,"company":"Shanghai Ark Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AK0901","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shanghai Ark Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Su Zhou YiHua Biotechnology Co. LTD","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Anyu Peibo","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Mental Health Center \/ Su Zhou YiHua Biotechnology Co. LTD","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mental Health Center \/ Su Zhou YiHua Biotechnology Co. LTD"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Su Zhou YiHua Biotechnology Co. LTD","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Anyu Peibo","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Mental Health Center \/ Su Zhou YiHua Biotechnology Co. LTD","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mental Health Center \/ Su Zhou YiHua Biotechnology Co. LTD"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Su Zhou YiHua Biotechnology Co. LTD","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Anyu Peibo","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Mental Health Center \/ Su Zhou YiHua Biotechnology Co. LTD","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mental Health Center \/ Su Zhou YiHua Biotechnology Co. LTD"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ASC-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Doris Meister","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BOT-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Doris Meister","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Doris Meister \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Doris Meister \/ Undisclosed"},{"orgOrder":0,"company":"Ivix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BP101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Ivix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ivix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ivix \/ Undisclosed"},{"orgOrder":0,"company":"Ivix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BP101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Ivix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ivix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ivix \/ Undisclosed"},{"orgOrder":0,"company":"Ivix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BP101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Ivix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ivix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ivix \/ Undisclosed"},{"orgOrder":0,"company":"Ovoca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BP-101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Ovoca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ovoca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ovoca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Ovoca Bio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"BP-101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forte Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Forte Biosciences \/ Ovoca Bio","highestDevelopmentStatusID":"10","companyTruncated":"Forte Biosciences \/ Ovoca Bio"},{"orgOrder":0,"company":"ChemRar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"RUSSIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CD-008-0045","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"ChemRar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChemRar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ChemRar \/ Undisclosed"},{"orgOrder":0,"company":"ChemRar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"RUSSIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CD-008-0045","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"ChemRar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChemRar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ChemRar \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Deprexil","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Deprexil","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DSP-5423P","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"DSP-5423P","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bionov","sponsor":"Seppic","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Extramel","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bionov","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionov \/ Seppic","highestDevelopmentStatusID":"10","companyTruncated":"Bionov \/ Seppic"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"HCP1302","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"HLD200","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironshore Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironshore Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin, Human","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"JNS001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"JNS001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Methylphenidate Polistirex","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating, Extended Release","sponsorNew":"Neos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmasoft","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Emoxypine Succinate","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pharmasoft","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmasoft \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmasoft \/ Undisclosed"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NMRA-335140","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NMRA-335140","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NMRA-335140","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NMRA-335140","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Synergy Research Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Odelepan","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"R-Pharm \/ Synergy Research Inc.","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Synergy Research Inc."},{"orgOrder":0,"company":"Bubba Nicholson","sponsor":"Tampa General Hospital | Otrimed Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Pheromone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bubba Nicholson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Bubba Nicholson \/ Tampa General Hospital | Otrimed Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Bubba Nicholson \/ Tampa General Hospital | Otrimed Clinical Research"},{"orgOrder":0,"company":"PharmaNeuroBoost","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"PPNB01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"PharmaNeuroBoost","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaNeuroBoost \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaNeuroBoost \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PPP011","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"McMaster University","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Probiostick","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sachet","sponsorNew":"McMaster University \/ Lallemand Health Solutions","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"Queen's University","sponsor":"Lallemand Health Solutions | McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Probiostick","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Queen's University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen's University \/ Lallemand Health Solutions | McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"Queen's University \/ Lallemand Health Solutions | McMaster University"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"RUSSIA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Prospekta","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLM1016","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Joint Child Health Project, Mauritius","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"MAURITIUS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Smartfish Omega","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Joint Child Health Project, Mauritius","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joint Child Health Project, Mauritius \/ University of Pennsylvania","highestDevelopmentStatusID":"10","companyTruncated":"Joint Child Health Project, Mauritius \/ University of Pennsylvania"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Microorganism","year":"2019","type":"Inapplicable","leadProduct":"Tanzania Association","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Toronto Association","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"TRI102","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Trigonella Foenum-Graecum Seed Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TV-44749","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TV-44749","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TV-44749","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"YY-162","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"YY-162","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"antidepressants (fluoxetine type): thioether derivatives||Undisclosed||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor||V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pherin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pherin Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pherin Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor||V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor||V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor||V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor||V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pherin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pherin Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pherin Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor||V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"AffaMed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.17999999999999999,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"AffaMed Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pherin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pherin Pharmaceuticals \/ VistaGen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pherin Pharmaceuticals \/ VistaGen Therapeutics"},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pherin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pherin Pharmaceuticals \/ VistaGen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pherin Pharmaceuticals \/ VistaGen Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"V1R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Niacin","moa":"VLDL\/LDL synthesis","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Voltage-gated calcium channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hamilton Health Sciences \/ McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ McMaster University"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Voltage-gated calcium channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"UT Southwestern Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Biotics \/ Undisclosed"},{"orgOrder":0,"company":"Bend Bioscience","sponsor":"Cingulate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"Dexmethylphenidate","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bend Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bend Bioscience \/ Cingulate Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Bend Bioscience \/ Cingulate Therapeutics"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Reviva Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"HONG KONG","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Loxapine","moa":"Serotonin 2c (5-HT2c) receptor | D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Azetukalner","moa":"KCNQ2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenon Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Osavampator","moa":"Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"}]
Find Psychiatry/Psychology Drugs in Phase III Clinical Development in UNITED STATES
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
